Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry

Eur Heart J. 2008 Sep;29(17):2108-15. doi: 10.1093/eurheartj/ehn270. Epub 2008 Jun 18.

Abstract

Aims: To evaluate the occurrence of late and very late stent thrombosis (ST) following elective drug-eluting stent (DES) implantation in unprotected left main coronary artery (LMCA) stenosis in a large multicentre registry.

Methods and results: All 731 consecutive patients who had sirolimus- or paclitaxel-eluting stent electively implanted in de novo lesions on unprotected LMCA in five centres were included. ST was defined according to Academic Research Consortium definitions. Four (0.5%) patients had a definite ST: three early (two acute and one subacute) and one late ST, no cases of very late definite ST were recorded. All patients survived from the event. Three patients had a probable ST. Therefore, 7/731 (0.95%) patients had a definite or a probable ST and all were on dual antiplatelet therapy at the time of the event. Possible (eight late and 12 very late) ST occurred in 20 (2.7%) patients. At 29.5 ± 13.7 months follow-up, a total of 45 (6.2%) patients had died; 31 (4.2%) of cardiac death. Ninety five (12.9%) patients had a target-vessel and 76 (10.4%) a target-lesion revascularization. Angiographic follow-up was performed in 548 patients (75%): restenosis occurred in 77 (14.1%) patients.

Conclusion: Elective treatment of LMCA stenosis with DES appears safe with a 0.9% incidence of definite and probable ST at 29.5 ± 13.7 months.

Publication types

  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Aged
  • Coronary Restenosis / prevention & control*
  • Drug-Eluting Stents*
  • Female
  • Graft Occlusion, Vascular / etiology*
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Myocardial Revascularization / methods
  • Paclitaxel / administration & dosage*
  • Registries
  • Sirolimus / administration & dosage*
  • Treatment Outcome
  • Tubulin Modulators / administration & dosage*

Substances

  • Tubulin Modulators
  • Paclitaxel
  • Sirolimus